XM does not provide services to residents of the United States of America.
E
E

EMS

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss Ems Chemie 9M sales down on weak demand in Europe and China

Swiss Ems Chemie 9M sales down on weak demand in Europe and China Oct 23 (Reuters) - Swiss chemicals firm Ems Chemie EMSN.S said on Wednesday its nine-month sales fell due to weak demand in its main markets Europe and China, and a strong Swiss franc, which appreciated as a safe haven currency. The company maintained its full-year guidance although it expects the weak market environment to persist in the fourth quarter.
C
E

Swiss stocks - Factors to watch on October 23

Swiss stocks - Factors to watch on October 23 ZURICH/GDANSK, Oct 23 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: COMPANY STATEMENTS EMS CHEMIE EMSN.S EMS Group Says 9M Net Sales reach CHF 1,589 Mln. KUEHNE UND NAGEL KNIN.S Kuehne Und Nagel 9M Net Turnover at CHF 18.0 Billion TEMENOS TEMN.S Third quarter results due.
E
K
T

EMS Group Says 9M Net Sales CHF 1,589 Mln

BRIEF-EMS Group Says 9M Net Sales CHF 1,589 Mln Oct 22 (Reuters) - Ems Chemie Holding AG EMSN.S : EMS GROUP - 9M NET SALES CHF 1,589 MILLION EMS GROUP - EBIT SIGNIFICANTLY HIGHER THAN PREVIOUS YEAR IN THIRD QUARTER EMS GROUP- SEES FY 2024 NET SALES SLIGHTLY BELOW PREVIOUS YEAR DUE TO CURRENCY EFFECTS AND NET OPERATING INCOME (EBIT) SLIGHTLY ABOVE P
E

Swiss stocks - Factors to watch on August 13

Swiss stocks - Factors to watch on August 13 ZURICH/GDANSK, Aug 13 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: COMPANY STATEMENTS SCHINDLER HOLDING AG SCHP.S Wins Avenues - Riyadh project in Saudi Arabia. TECAN GROUP TECN.S Reports HY adjusted EBITDA of 67.9 million Swiss francs. NOVARTIS NOVN.S Lost initial bid to block generic of best-selling heart drug.
E
N
S

Swiss stocks - Factors to watch on August 9

Swiss stocks - Factors to watch on August 9 Aug 9 - Here are some of the main factors that may affect Swiss stocks on Friday: ANALYSTS' VIEWS ZURICH INSURANCE GROUP ZURN.S : HSBC CUTS TARGET PRICE TO CHF 515 FROM CHF 525 GALDERMA GROUP AG GALD.S : JP MORGAN INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET CHF 90 ANNUAL GENERAL MEETINGS EMS CHEMIE HOLDING AG EMSN.S - 16 CHF/shr dividend proposed ECONOMY Swiss Q3 Consumer Confidence due at 0700 GMT.
E
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.